Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danazol in Fanconi Anemia and Dyskeratosis Congenita
NCT01001598Phase 2Terminated
- Sponsor
- Boston Children's Hospital
- Start
- Nov 2009
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of danazol in Fanconi anemia (FA), dyskeratosis congenita (DC), sponsored by Boston Children's Hospital. Started Nov 2009; status: terminated.
02
Drugs
danazol
03
Conditions
Fanconi anemia (FA)dyskeratosis congenita (DC)
Beyond the preview
Go deeper on NCT01001598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001598.